Reduction of metastatic load to liver after intraarterial hepatic yttrium-90 radioembolization as evaluated by [18F]fluorodeoxyglucose positron emission tomographic imaging

Journal of Vascular and Interventional Radiology

Volumn 16, Issue 8, 2005, Pages 1101-1106

  Wong, Ching Yee Oliver ^a   Qing, Feng ^a   Savin, Michael ^a   Campbell, Janice ^a   Gates, Vanessa L ^b   Sherpa, Kanchi M ^a   Lewandowski, Robert J ^a   Nagle, Conrad ^a   Salem, Riad ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MACROSALB TC 99M; MICROSPHERE; THERASPHERE; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; FEMALE; HUMAN; HYPERBILIRUBINEMIA; LIVER ANGIOGRAPHY; LIVER METASTASIS; LIVER SCINTISCANNING; MALE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ATTENUATION; RADIATION DOSE DISTRIBUTION; RADIOEMBOLIZATION; RADIOISOTOPE THERAPY; SOLID TUMOR; VISUAL ANALOG SCALE;

EID: 23844455583     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000168104.32849.07     Document Type: Article

References (27)

1. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ami Surg 2004; 240:438-447.
2. Arulampalam THA, Costa DC, Loizidou M, Visvikis D, Ell PJ, Taylor I. Positron emission tomography and colorectal cancer. Br J Surg 2001; 88: 176-189.
3. Silvestri GA, Tanoue LT, Margolis ML, Barker J, Detterbeck F; American College of Chest Physicians. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123(1 suppl):147S-156S.
4. Eubank WB, Mankoff DA, Vesselle HJ, et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics 2002; 22:5-17.
5. Burton MA, Gray BN, Kelleher DK, Klemp PF. Selective internal radiation therapy: validation of intraoperative dosimetry. Radiology 1990; 175: 253-255.
6. 90Y-microspheres. J Nucl Med 2000; 41:1673-1681.
7. Ho S, Lau WY, Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24: 293-298.
8. Gray BN, Anderson JE, Burton MA, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg 1992; 62: 105-110.
9. Wong CY, Salem R, Raman S, Gates VL, Dworkin HJ. Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging 2002; 29:815-820.
10. Wong CY, Salem R, Qing F, et al. Metabolic response after intraarterial [Y90]-glass microsphere treatment for colorectal liver metastases: comparison of quantitative and visual analyses by 18F-FDG PET. J Nucl Med 2004; 45: 1892-1897.
11. Salem R, Lewandowski R, Oman B, et al. Use of yttrium-90 glass microspheres (Therasphere®) for the treatment of unresectable hepatocellular carcinoma (HCC) in patients with portal vein thrombosis. J Vasc Interv Radiol 2004; 15:335-345.
12. Herba MJ, Illescas FF, Thirlwell MP, et al. Hepatic malignancies: Improved treatment with intraarterial yttrium-90. Radiology 1988; 169:311-314.
13. Stubbs RS, Carman RJ, Mitchell AW. Selective internal radiation therapy with 90-yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg 2001; 5:294-302.
14. Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Eur J Nucl Med 1997; 24:293-298.
15. Berger MJ. Distribution of absorbed dose around point sources of electrons and beta particles in water and other media. J Nucl Med 1971; NM/MIRD suppl 5. Pamphlet No. 7: 7-23.
16. Snyder WS, Ford MR, Warner GG, Watson SB. Absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet No. 11. New York: Society of Nuclear Medicine, 1975-1976.
17. Patel N, Sacks D, Patel RI, et al. SIR reporting standards for the treatment of acute limb ischemia with use of transluminal removal of arterial thrombus. J Vasc Interv Radiol 2003; 14(suppl):S453-S465.
18. Selzner M, Hany TF. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg 2004; 240:1027-1036.
19. 18F-FDG PET on managing patients with colorectal cancer: the referring physician's perspective. J Nucl Med 2001; 42:586-590.
20. Rohren EM, Paulson EK, Hagge R, et al. The role of F-18 FDG positron emission tomography in preoperative assessment of the liver in patients being considered for curative resection of hepatic metastases from colorectal cancer. Clin Nucl Med 2002; 27:550-555.
21. Valk PE, Abella-Columna E, Hasemann MK, et al. Whole body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer. Arch Surg 1999; 134:503-511.
22. Ogunbiyi OA, Flanagan FL, Dehdashti F, et al. Detection of recurrent and metastatic colorectal cancer: comparison of positron emission tomography and computed tomography. Ann Surg Oncol 1997; 4:613-620.
23. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001; 21:4285-4300.
24. Barker DW, Zagoria RJ, Morton KA, et al. Evaluation of liver metastases after radiofrequency ablation: utility of 18F-FDG PET and PET/CT. AJR Am J Roentgenol 2005; 184:1096-1102.
25. Van Hazel G, Blackwell A, Anderson J, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88:78-85.
26. Rubin D, Nutting C, Jones B. Metastatic breast cancer in a 54-year-old woman: integrative treatment with yttrium-90 radioembolization. Integr Cancer Ther 2004; 3:262-267.
27. Park KC, Schwimmer J, Shepherd JE, et al. Decision analysis for the cost-effective management of recurrent colorectal cancer. Ann Surg 2001; 233:310-319.